| THE EVOLUTION - THE VILLAIN OVERRIDE |
|
| Year : 2017 | Volume
: 4
| Issue : 1 | Page : 53-62 |
|
|
Drug-Resistant tuberculosis: Key strategies for a recalcitrant disease
Rupak Singla
Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Disease, New Delhi, India
Correspondence Address:
Rupak Singla
Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Disease, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/astrocyte.astrocyte_55_17
|
|
|
Over half million cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year globally, and a significant number of them are affected by extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. There is limited access to reliable diagnostic facilities to drug-resistant (DR) TB in most developing countries. The treatment of MDR/XDR-TB is unfortunately very expensive, long, and toxic and the success rate is largely unsatisfactory (<50% among MDR-TB and <20% among cases with resistance patterns beyond XDR).The aim of this review is to summarize the available evidence-based updated international recommendations to diagnostic methods and treatment of MDR/XDR-TB, and briefly discuss the shorter MDR-TB regimen and the role of newly developed drugs as well as repurposed drugs. This review will help the reader to formulate treatment regimen for DR-TB patients based on currently available newer rapid diagnostic tests.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
